The fact that HER-2 overexpression and amplification have been associated with poor prognosis in ovarian and breast cancers [36, 37], led to the development and approval of trastuzumab mAb to target HER-2 in breast tumors [38]. The gene discussed is ERBB2; the disease is breast neoplasm.